A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

January 22, 2020

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Cholangiocarcinoma
Interventions
DRUG

E7090

E7090 tablets orally.

Trial Locations (56)

Unknown

The First Affiliated Hospital of Bengbu Medical College, Bengbu

Anhui Provincial Hospital, Hefei

Beijing Tsinghua Chang Gung Memorial Hospital, Beijing

Beijing Youan Hospital Affiliated to Capital Medical University, Beijing

Beijng Cancer Hospital, Beijing

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

Peking Union Medical University Hospital, Beijing

Fujian Provincial Hospital, Fuzhou

The First Affiliated Hospital of Xiamen University, Xiamen

Guangdong Province Traditional Chinese Medical Hospital, Guangzhou

The First Affiliated Hospital, Sun Yat-sen Univeristy, Guangzhou

Peking University Shenzhen Hospital, Shenzhen

Affiliated Hospital of Hebei University, Baoding

Affilicataed Cancer Hospital of Harbin Medical University, Harbin

Henan Cancer Hospital, Zhengzhou

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan

Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan

Hunan provincial people's hospital, Changsha

The Third Xiangya Hospital of Central South University, Changsha

Xiangya Hospital of Central South University, Changsha

Jiangsu Province Hospital, Nanjing

Nantong Tumor Hospital, Nantong

The First Affiliated Hospital of Soochow, Suzhou

Jilin Cancer Hospital, Changchun

Shandong Cancer Hospital, Jinan

Fudan University Shanghai Cancer Center, Shanghai

Zhongshan Hospital Fudan University, Shanghai

West China Hospital of Sichuan University, Chengdu

The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou

The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

Ningbo First Hospital, Ningbo

Eisai Trial Site 10, Nagoya

Eisai Trial Site 16, Kashiwa

Eisai Trial Site 11, Matsuyama

Eisai Trial Site 14, Matsuyama

Eisai Trial Site 2, Sapporo

Eisai Trial Site 8, Kanazawa

Eisai Trial Site 7, Yokohama

Eisai Trial Site 23, Tsu

Eisai Trial Site 22, Sendai

Eisai Trial Site 13, Hirakata

Eisai Trial Site 17, Suita

Eisai Trial Site 9, Sunto-gun

Eisai Trial Site 5, Bunkyo-ku

Eisai Trial Site 4, Chuo-ku

Eisai Trial Site 6, Koto-ku

Eisai Trial Site 3, Mitaka

Eisai Trial Site 1, Ube-Shi

Eisai Trial Site 18, Chiba

Eisai Trial Site 15, Fukuoka

Eisai Trial Site 20, Kagoshima

Eisai Trial Site 19, Kochi

Eisai Trial Site 12, Kyoto

Eisai Trial Site 21, Niigata

Eisai Trial Site 24, Wakayama

All Listed Sponsors
lead

Eisai Co., Ltd.

INDUSTRY